Get access

Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations


  • Relevant conflicts of interest/financial disclosures: This study was supported by the Parkinson's Disease Foundation, New York, New York. Drs. Goldman and Goetz have received research support from the Parkinson's Disease Foundation. Dr. Berry-Kravis has consulted and had clinical trial funding from Novartis, Roche, Seaside Therapeutics and Neuropharm LTD for projects unrelated to Parkinson's Disease or hallucinations. Full financial disclosures and author roles may be found in the online version of this article.

No abstract is available for this article.